Madrigal Pharmaceuticals, Inc. MDGL Amortization and interest accretion related to operating leases
Amortization and interest accretion related to operating leases at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept mdgl:OperatingLeaseRightOfUseAssetPeriodicReductionIncrease.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s amortization and interest accretion related to operating leases.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s amortization and interest accretion related to operating leases?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported amortization and interest accretion related to operating leases of $408K in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s amortization and interest accretion related to operating leases changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s amortization and interest accretion related to operating leases increased by 628.6% year-over-year, from $56K to $408K.
- What does amortization and interest accretion related to operating leases mean?
- The non-cash cost of using leased assets over time.
- How do you interpret amortization and interest accretion related to operating leases?
- An increase suggests a larger footprint of leased assets, impacting long-term fixed obligations.
- How does amortization and interest accretion related to operating leases compare across companies?
- Standard for all companies reporting under modern lease accounting standards (ASC 842/IFRS 16).